Ipamorelin: A Selective Growth Hormone Secretagogue for Laboratory Research

Introduction

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue (GHS) that acts as an agonist at the ghrelin receptor (GHS-R1a). With the CAS number 170851-70-4 and the structural sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, ipamorelin has been extensively studied in preclinical research for its ability to stimulate growth hormone (GH) release with high selectivity and minimal off-target effects. Unlike earlier growth hormone secretagogues such as GHRP-6, ipamorelin demonstrates a notably clean pharmacological profile, making it a valuable and precise research tool in endocrinology and metabolic biology.

Molecular Structure & Properties

Ipamorelin has a molecular formula of C₃₈H₄₉N₉O₅ and a molecular weight of approximately 711.87 Daltons. The incorporation of non-natural amino acids — including alpha-aminoisobutyric acid (Aib) at position 1 and D-2-naphthylalanine (D-2-Nal) at position 3 — confers resistance to proteolytic degradation and enhances receptor binding affinity. The C-terminal amidation further stabilizes the peptide in biological matrices, contributing to its utility in experimental protocols requiring sustained receptor engagement.

Research Findings

In preclinical studies, ipamorelin has been shown to produce dose-dependent increases in plasma GH levels in rodent models, with a rapid onset and short duration of action consistent with pulsatile GH secretion patterns [1]. Critically, research has demonstrated that ipamorelin does not significantly stimulate the release of ACTH, cortisol, prolactin, or aldosterone at GH-releasing doses — a key distinction from non-selective secretagogues like GHRP-6, which activate multiple neuroendocrine pathways [2]. This selectivity makes ipamorelin particularly valuable for studies that require isolated examination of the GH axis without confounding hormonal perturbations.

Studies in aged rodent models have investigated ipamorelin's effects on bone mineral density, lean body mass, and fat mass, with findings suggesting that GH secretagogue-mediated GH release can partially reverse age-associated changes in body composition in experimental settings [3]. Research in porcine models has also characterized ipamorelin's pharmacokinetics and tissue distribution, providing foundational data for understanding its behavior in larger mammalian systems [4].

Mechanism of Action (in Experimental Models)

Ipamorelin exerts its primary effects through agonism of the GHS-R1a receptor, a G-protein coupled receptor expressed predominantly in the pituitary gland, hypothalamus, and peripheral tissues including the gastrointestinal tract and adipose tissue. Upon receptor binding, ipamorelin activates Gq/11 protein signaling, stimulating phospholipase C (PLC) activity and increasing intracellular calcium (Ca²⁺) concentrations via inositol trisphosphate (IP₃)-mediated release from the endoplasmic reticulum [5].

In pituitary somatotroph cells, this calcium signaling cascade triggers the exocytosis of stored GH granules, producing the characteristic pulsatile GH release observed in experimental models. Ipamorelin's selectivity is attributed to its inability to significantly activate Gs protein pathways or interact with receptors for ACTH, prolactin, or cortisol at pharmacologically relevant concentrations, distinguishing it from less selective secretagogues in the research literature [2].

Research Applications

Ipamorelin is employed across a range of research contexts, including studies of pituitary function, GH axis regulation, age-related changes in body composition, bone metabolism, and gastrointestinal motility. Its high selectivity and well-characterized receptor pharmacology make it a preferred tool for investigators seeking to study GH secretagogue biology without the confounding effects of multi-target receptor activation.

Research has also explored ipamorelin in models of post-surgical recovery and gastrointestinal dysmotility, where GHS-R1a activation in enteric neurons has been associated with improvements in gut motility parameters in experimental settings [6]. Additionally, its combination with growth hormone-releasing hormone (GHRH) analogues such as CJC-1295 has been studied to characterize synergistic effects on GH pulse amplitude and frequency in preclinical models.

All research involving ipamorelin is conducted for research purposes only within controlled laboratory environments, aimed at advancing understanding of the GH axis and growth hormone secretagogue pharmacology.

This article is intended for scientific and educational reference within a laboratory research context only. All products sold by Pure Pharm Peptides are for research use only and are not intended for human or animal consumption.

References

1. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
2. Johansen, P. B., et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth, 63(3), 301–309.
3. Svensson, J., et al. (2000). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 83(2), 362–369.
4. Ankersen, M., et al. (1998). Discovery of [D-Pip]ipamorelin, a novel GH-secretagogue with potent and long-lasting effects in rats. Bioorganic & Medicinal Chemistry Letters, 8(22), 3207–3212.
5. Smith, R. G., et al. (1997). A role for the growth hormone releasing hexapeptide receptor in somatostatin-mediated feedback. Endocrinology, 138(2), 445–448.
6. Trudel, L., et al. (2002). Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. American Journal of Physiology - Gastrointestinal and Liver Physiology, 282(6), G948–G952.